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013.03.0Abstract Hypertension is a common health problem in Egypt. It has a high prevalence, whereas its
rates of awareness, treatment and control are low. In 60% of patients, hypertension is complicated
by the presence of other cardiovascular risk factors, this adds to increased cardiovascular morbidity
and mortality. Management of hypertension in Egypt is not easy because of treatment costs- a com-
mon cause of interruption of therapy-, inadequate physician training and inefﬁcient primary health
care system. Measures to improve blood pressure control include better physicians education and a
viable health care system. Development of national hypertension guidelines and their implementa-
tion is essential in physician education programs. Consideration is given in guidelines to the diag-
nosis and treatment of hypertension in poor resource sitting: a higher threshold for diagnosis and
initiation of pharmacological treatment is recommended, while priority in drug therapy is given to
less expensive medication.
ª 2013 Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Cardiology.Data from the Egyptian National hypertension Project
(NHP) showed that hypertension is common among Egyp-
tians. In the years from 1991–1993, 26.3% of adult Egyptians
had high blood pressure.1–3 More than 50% of individuals old-
er than 60 years suffered from hypertension. At present, if the
same prevalence rates do not change, it is predicted that with
an Egyptian population of more than 80 million, there will
be approximately 15 million with hypertension and about
7 million will be in need of lifelong drug treatment and regular
follow-up. The problem is complicated by the low awarenessen, Cairo 11111, Egypt. Tel.:
mobile: +20 0122273816.
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05rates, only 38% of hypertensive Egyptians were aware of hav-
ing high blood pressure, only 24% were receiving treatment,
whereas control rates (<140/90 mmHg) were 8%.4,5 Other
cardiovascular risk factors namely hypercholesterolemia, in-
creased LDL-cholesterol, low HDL-cholesterol, hypertriglyc-
eridemia, diabetes, impaired glucose tolerance and obesity
were present in 60% of hypertensive patients. Target organ
damage was present in patients with more than stage I hyper-
tension (P160/100 mmHg), e.g. ECG- LVH in 20%, coronary
artery disease (CAD) 16%, systolic heart failure in 5% and re-
nal failure in 3.2%. Egyptians have one of the highest mortal-
ity rates secondary to CAD worldwide. Hypertension is an
established major risk factor for CAD.
These epidemiologic data underscore the need for develop-
ing national hypertension guidelines aiming at improving the
rates of awareness, treatment and control of hypertension with
the ﬁnal goal of preventing or delaying target organ damage,gyptian Society of Cardiology.
234 M.M. Ibrahimhypertensive complications, cardiovascular and renal events
and decreasing morbidity and mortality.
Because of its high prevalence, the treatment of hyperten-
sion puts economic pressure on the Egyptian economy. Drug
cost is the major determinant of the cost of care, responsible
for around 80% of the total cost of hypertension care within
the ﬁrst year of treatment. In Egypt, the drug cost of hyperten-
sion (total antihypertensive market) during the year 2011 was
more than one billion Egyptian pounds, a dramatic increase
from 600 million in 2007.
In view of Egypt’s limited ﬁnancial resources and the lim-
ited government spending on health which equals annually
42 USD per capita (year 2008), while total annual/capita
expenditure on health is 124 USD compared with 3925 USD
in USA, guidelines should give priority to the cost of care. Fur-
thermore, more than 58% of spending on health care in Egypt
is out of the pocket. Choices must be made as to how the lim-
ited budget is spent. Therefore, countries with limited re-
sources cannot treat everyone with BP beyond the deﬁned
threshold stated in the international guidelines.6,7 A higher
threshold of >150/95 mmHg for the initiation of therapy
might be considered and priority should be given to high risk
patients. On the other hand, drugs of ﬁrst choice should be the
least expensive such as thiazide, beta adrenergic blockers and
generic forms of drugs. Patients will not adhere to drugs that
they cannot afford.
Difﬁculties in blood pressure control in Egypt and other
developing countries
- There is lack of reliable evidence about the effects of treat-
ment from drug trials. Most trials are conducted in higher-
income countries.
- Treatment is not affordable or practical for most develop-
ing countries.
- Need to base treatment policies on estimated absolute dis-
ease risk rather than on BP levels alone. Assessment of risk
requires laboratory testing.
- Blood pressure lowering treatment may need to be
restricted to higher risk individuals, moderate-to-severe
hypertension or history of cardiovascular or renal disease.
- Absence of functional primary health care services means
that even free or inexpensive drugs cannot be reliably pro-
vided to those in need.- Financial incentives from industry for health care providers
to selectively prescribe more expensive drugs despite bring-
ing no clear advantage over cheaper drugs, such as
diuretics.
- No regular hospital or outpatient records.
- Priority of the health care system is given to acute
conditions.
Measures to improve BP control
- Need for primary health care system that:
n Can identify those at high risk.
n Ensure regular monitoring of the health status.
n Provide an uninterrupted appropriate and affordable
treatment supply.
- Identifying those at high risk
n Screening algorithms: age, gender, weight, height, car-
diovascular history, and urine dip stick.
- Long term monitoring of those at high risk
- Access to an uninterrupted and affordable drug supply.
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